Abstract:During anti-TNF therapy, inflammatory bowel disease (IBD) patients either with or without latent tuberculosis infection (LTBI) active TB can develop. It remains unclear whether IBD patients without LTBI receiving prophylactic anti-TB has any clinical value or which prophylactic anti-TB strategy (for both LTBI and non-LTBI or only for LTBI) is superior. Furthermore, the optimum treatment regimen for IBD patients with LTBI receiving infliximab (IFX) in China are both unclear. This study was to investigate the optimal prophylactic anti-TB strategies and treatment regimens in Chinese IBD subjects receiving IFX treatment. IBD patients receiving IFX at 18 academic hospitals in China were enrolled. Incidence and risk factors for active TB during IFX treatment were studied. The incidence of active TB in IBD patients with IFX therapy receiving selective (strategy I: only anti-TB prophylaxis for LTBI) and conventional (strategy II: anti-TB prophylaxis for both LTBI and non-LTBI) prophylactic anti-TB strategies was compared. Further subgroup analysis investigated the incidence rate of active TB in LTBI and non-LTBI patients and examined effective prophylactic treatment regimens for LTBI. A total of 1968 IBD patients receiving IFX treatment were enrolled. The incidence rate of TB was 999.07 per 100000 population per year. At baseline, 166 cases (8.43%) tested positive for LTBI and 1802 cases negative for LTBI prior to IFX treatment. Of 1433 cases receiving strategy I and 483 cases receiving strategy II, 10 and 5 cases developed active TB, respectively. Figure 1. The incidence of active TB in IBD patients with IFX therapy receiving different strategy. And the incidence of active TB was not significantly reduced in IBD patients receiving strategy I compared with those receiving strategy II (0.07% vs. 1.04%, p = .67). The incidence of active TB (2.63% vs. 11.54%, p = .048) was significantly reduced but not eradicated in LTBI patients receiving prophylactic anti-TB therapy during IFX treatment, but these findings were not seen in non-LTBI patients. Figure 2. The incidence of active TB in LTBI and non-LTBI patients. Furthermore, INH treatment for 6 months significantly decreased the incidence rate of active TB (0% vs. 11.54%, p = 0.045) in LTBI patients. Selective prophylactic anti-TB strategy may be superior for Chinese patients with IBD receiving IFX treatment and INH treatment for 6 months could be an effective treatment regimen for LTBI.

IGRA-based INH regimen for prevention of active tuberculosis after kidney transplantation: a single-center retrospective study

Screening for Latent Tuberculosis Infection in Solid Organ transplant recipients to predict active disease: a systematic review and meta-analysis of diagnostic studies

P482 Selective Prophylactic Anti-Tuberculosis Strategy is Superior for Chinese Patients with Inflammatory Bowel Disease Receiving Infliximab Treatment: a Multi-Centre Retrospective Study

P568 Does Infliximab Therapy Increase Incidence of Tuberculosis in Patients with Inflammatory Bowel Disease in an Endemic Area: a Nationwide Study from China

Risk of progression to active tuberculosis for indeterminate interferon-gamma release assay in immunocompromised individuals: A systematic review and meta-analysis

Effect of Different Induction Therapies on the Clinical Outcomes of ABO-incompatible Living Donor Kidney Transplantation Recipients

Tuberculosis in Kidney Transplant Recipients: A Nationwide Cohort in a Low Tuberculosis Incidence Country

Tuberculosis treatment without rifampin in kidney/kidney–pancreas transplantation: A case series report

Long-term Effectiveness of Anti-Interleukin-2 Receptor Antibodies Vs.rabbit Antithymocyte Globulin As Induction Therapy in Kidney Transplantation

Interferon-Gamma Release Assay Combined with Renal Indicators to Reduce the False-Negativity of Latent Tuberculosis Infection in End-Stage Renal Disease with Hemodialysis Patients

Investigation on status quo of tuberculosis screening in 1711 patients with inflammatory bowel diseases before infliximab therapy in China

Basiliximab vs. No Induction Therapy in Kidney Transplant Recipients with a Low Immunological Risk Profile Receiving Tacrolimus/Mycophenolate/Steroids Maintenance Immunosuppression

Effect of Different Induction Immunosuppression on the Incidence of Infectious Complications after Kidney Transplantation—Single Center Study

Kidney transplantation in patients on anti‐tubercular therapy: A single centre observational study

Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti-TNF therapy in a tuberculosis endemic region

Risk of Tuberculosis During Infliximab Therapy for Inflammatory Bowel Disease, Rheumatoid Arthritis, and Spondyloarthropathy: A Meta-Analysis

P-030 Infliximab and Tuberculosis Infection

Progress on Diagnosis and Treatment of Latent Tuberculosis Infection

Performance of two interferon-gamma release assays for tuberculosis infection screening in Kawasaki children before immunosuppressive therapy

Diagnostic delay and mortality of active tuberculosis in patients after kidney transplantation in a tertiary care hospital in China

Impact of the interferon-γ release assay and glomerular filtration rate on the estimation of active tuberculosis risk before bronchoscopic examinations: a retrospective pilot study